GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Durata Therapeutics Inc (FRA:DTA) » Definitions » SpecialCharges

Durata Therapeutics (FRA:DTA) SpecialCharges


View and export this data going back to . Start your Free Trial

What is Durata Therapeutics SpecialCharges?

Special Charges only applies to banks.


Durata Therapeutics (FRA:DTA) Business Description

Traded in Other Exchanges
N/A
Address
Durata Therapeutics Inc was incorporated under the laws of the State of Delaware on November 4, 2009. The Company, along with its subsidiaries, is a development stage pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. The Company recently completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI. Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing.